CCL2 and melanoma: Overwhelming evidence supported targeting the CCL2–CCR2 axis in various cancer types including in melanoma as candidates for immunotherapy, especially in combination with ICBs, which also echoes our results of correlations between the expression of CCR2 and IC genes (41, 42).